External stimulus responsive inorganic nanomaterials for cancer theranostics

Cancer is a highly intelligent system of cells, that works together with the body to thrive and subsequently overwhelm the host in order for its survival. Therefore, treatment regimens should be equally competent to outsmart these cells. Unfortunately, it is not the case with current therapeutic pra...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2019-01, Vol.138, p.18-40
Main Authors: M., Sheikh Mohamed, Veeranarayanan, Srivani, Maekawa, Toru, D., Sakthi Kumar
Format: Article
Language:English
Subjects:
Animals
Cancer
Clinical trials
Electromagnetic Radiation
External stimulus
Humans
Inorganic nanoparticles
Magnetic Fields
Nanostructures - administration & dosage
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - radiotherapy
Theranostic Nanomedicine
Theranostics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is a highly intelligent system of cells, that works together with the body to thrive and subsequently overwhelm the host in order for its survival. Therefore, treatment regimens should be equally competent to outsmart these cells. Unfortunately, it is not the case with current therapeutic practices, the reason why it is still one of the most deadly adversaries and an imposing challenge to healthcare practitioners and researchers alike. With rapid nanotechnological interventions in the medical arena, the amalgamation of diagnostic and therapeutic functionalities into a single platform, theranostics provides a never before experienced hope of enhancing diagnostic accuracy and therapeutic efficiency. Additionally, the ability of these nanotheranostic agents to perform their actions on-demand, i.e. can be controlled by external stimulus such as light, magnetic field, sound waves and radiation has cemented their position as next generation anti-cancer candidates. Numerous reports exist of such stimuli-responsive theranostic nanomaterials against cancer, but few have broken through to clinical trials, let alone clinical practice. This review sheds light on the pros and cons of a few such theranostic nanomaterials, especially inorganic nanomaterials which do not require any additional chemical moieties to initiate the stimulus. The review will primarily focus on preclinical and clinical trial approved theranostic agents alone, describing their success or failure in the respective stages. [Display omitted]
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2018.10.007